ADCYAP1R1 and cancer: In conclusion, our results indicate that PAC1 signaling may be one of the mechanisms induced by EA to protect against cisplatin-induced neurotoxicity and immunosuppression in cancer patients, and PAC1-agonists may provide therapeutic advantages to treat patients with advanced neurotoxicity or neuropathies limiting EA efficacy.